Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?

Key Takeaways Globus Medical gains from U.S. Spine growth and 35% y/y rise in core trauma business.GMED's recent Nevro deal expands market reach, unlocking a $2.5B musculoskeletal opportunity.New product launches like DuraPro and Verzera highlight GMED's R&D focus.Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from ...